



ERA® is a diagnostic test patented by Igenomix in 2009

3 in every 10 implantation failure patients have a displaced window of implantation*

ERA analyzes 248 genes related to endometrial receptivity

Why choose Igenomix ERA test?



• ERA is backed by 25 publications 16 from Igenomix and 9 external publications.



 Randomized study in progress to assess its applicability in patients without any prior ART.

(ClinicalTrials.gov Identifier: NCT01954758)



• Algorithms based on machine learning technologies.




• ERA allows clinicians to identify transition phases with 12 hours shifts.

v. 2021

Endometrial ERA® Receptivity Analysis





v. 2021

16



When is a second biopsy needed?

90 % of cases don't need a second biopsy. The second biopsy is only required under two circumstances:

- Patients with a "Pre-receptive" result, that need 2 days more on progesterone.
- Patients with a "Post-receptive" result.

IGENOMIX DATA

